Clinical Genomics to Present Data at ASCO GI Supporting Clinical Utility of Colvera™ in Assessing and Monitoring Patients Following Surgical Resection of Colorectal Cancer

BRIDGEWATER, N.J., Jan. 18, 2017 -- Clinical Genomics, a private company marketing innovative diagnostic tools for colorectal cancer, today announced that data demonstrating the utility of Colvera™, its 2-gene blood test, in detecting minimal residual disease and its relation to stage in patients with colorectal cancer (CRC) will be presented in two posters at the American Society of Clinical Oncology 2017 Gastrointestinal Cancers Symposium (ASCO GI), taking place in San Francisco from January 19-21.

Studies selected for presentation at the meeting include:

• Predictors of circulating tumor-derived methylated BCAT1 and IKZF1 DNA in colorectal cancer patients.
  Presenter: Michael C. Dugan, M.D.
  Abstract Number: 567
  Poster Board Number: C7

• The relationship between the degree of aberrant methylation in colorectal cancer tissue and appearance of tumor-derived DNA in blood.
  Presenter: Lawrence LaPointe, Ph.D.
  Abstract Number: 579
  Poster Board Number: C19

Data will be presented during Poster Session C: Cancers of the Colon, Rectum, and Anus, on January 21 from 7:00 – 7:55 a.m. PT and 12:30 – 2:00 p.m. PT.

CRC is one of the leading causes of cancer-related deaths worldwide, accounting for more than 600,000 deaths each year. Among individuals undergoing surgical treatment for CRC, recurrence occurs in 30 to 50 percent of all cases, the majority of which present in the first two to three years following initial diagnosis and treatment.

About Clinical Genomics
Clinical Genomics is a privately held biotechnology company developing and marketing innovative products for colorectal cancer (CRC) diagnosis. With a broad intellectual property portfolio consisting of more than 95 patents, Clinical Genomics sells colorectal cancer screening and monitoring solutions. Via its wholly-owned subsidiary Enterix Inc., the company offers the user-friendly, patient-preferred colorectal cancer screening InSure^® FIT™ assay, an FDA-cleared fecal immunochemical test that detects blood in the stool. InSure FIT is marketed as a healthcare screening service in Australia. In 2016, Clinical Genomics launched Colvera™, a sensitive and specific blood-based circulating tumor DNA (ctDNA) test for colorectal cancer recurrence monitoring that detects methylated DNA from two genes, BCAT1 and IKZF1.

Clinical Genomics has offices and CLIA-registered laboratories in Bridgewater as well as FDA-registered and TGA-licensed IVD manufacturing in Edison, New Jersey and Sydney, Australia and a NATA-accredited laboratory in North Ryde, NSW Australia.

For more information, please visit www.colveratest.com and www.clinicalgenomics.com.

Media Contact:
Danielle Lewis, Lazar Partners
(212) 843-0211 or (917) 907-4239
[email protected]